Novel cancer therapies targeting key cancer pathways
We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.
BROKER REPORT
The broker reports included on this page of the website have not been commissioned or endorsed by Prescient Therapeutics Limited (Prescient) or its officers and are provided for information purposes only. The information contained in these report is not produced by Prescient and is not intended to be investment or financial product advice given by Prescient. Prescient recommends recipients of the reports make their own assessment of Prescient before making any investment decision. Any inquiries with respect to the reports should be directed to the relevant issuer of the report.
OUR COMPANY
Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.
OUR SCIENCE
Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.
LATEST NEWS
| 18/11/2019 | PTX in new CAR-T collaboration | |
| 14/11/2019 | 1st patient dosed in trial for first in class drug PTX-100 | |
| 08/11/2019 | Receipt of R&D Tax Rebate | |
| 31/10/2019 | Prescient Ausbio Ras Presentation | |
| 30/10/2019 | September 2019 Appendix 4C - Quarterly | |
| 16/10/2019 | Notice of Annual General Meeting/Proxy Form | |
| 26/08/2019 | Appendix 4E and 2019 Annual Report |